Sustained Complete Response to Trastuzumab Deruxtecan Beyond Treatment Discontinuation in a Heavily Pretreated HER2-Positive Breast Cancer Patient with Skin Metastases: A Case Report. The gene discussed is ERBB2; the disease is breast carcinoma.